Interestingly, melanoma cells in a highly differentiated and melanocytic state, characterized by MITFhigh, expression have also been shown to play a role in resistance to BRAF and MEK targeted therapies, via the rheostatic (on/off) regulation of the transcription factors, PAX3 and BRN2 (51, 69). This evidence concerns the gene MAP2K7 and melanoma.